Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma

This multicentre, open-label, single-arm Phase II study investigates the efficacy of ivonescimab, a bispecific antibody targeting VEGF and PD-1, in patients with pleural mesothelioma (PM) who have relapsed after prior immunotherapy and standard chemotherapy. The trial plans to enroll 38 participants across approximately 20 centers, administering ivonescimab at a dose of 20 mg/kg every 3 weeks. The primary endpoint is to achieve a disease control rate (DCR) of at least 55% at 12 weeks, challenging the null hypothesis of a DCR of 30% or less. Secondary outcomes and safety profiles will be monitored, although specific adverse event data is not yet available. The study's design allows treatment continuation for up to 2 years or until disease progression or unacceptable toxicity occurs. This trial could potentially establish ivonescimab as a viable second or third-line treatment option, pending results.

Imagine facing pleural mesothelioma, a tough lung cancer, and finding out that your previous treatments aren't working anymore. This situation is a harsh reality for many patients, as the disease can be stubborn and resistant to standard therapies like chemotherapy and immunotherapy. Now, there's a new glimmer of hope: a drug called ivonescimab is being tested for patients whose cancer has returned after these treatments. In this study, 38 patients will receive ivonescimab every three weeks for up to two years. The goal is to see if this drug can help control the disease better than previous options. If it works, it could mean fewer patients experiencing disease progression and more time with their loved ones. However, it's important to remember that this is still in the testing phase, and we won't know the full results for a while. Patients should stay informed and discuss all available options with their healthcare team as this research unfolds.